A Study of CDX-1140 in Patients With Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03329950 |
|
Recruitment Status :
Recruiting
First Posted : November 6, 2017
Last Update Posted : June 28, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Melanoma Non-small Cell Lung Cancer Breast Cancer Gastric Cancer Renal Cell Carcinoma Ovarian Cancer Cholangiocarcinoma Bladder Urothelial Carcinoma Pancreatic Adenocarcinoma Colorectal Cancer Esophageal Cancer Hepatic Cancer Head and Neck Cancer | Drug: CDX-1140 | Phase 1 |
CDX-1140 is a fully human monoclonal antibody that binds to a cell receptor called CD40 found on certain cells to activate the immune system which may promote anti-tumor effects.
This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140.
Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several levels of CDX-1140. The first part of the study will test the safety profile of CDX-1140 and determine which dose(s) of CDX-1140 will be studied in the expansion portion of the study.
Up to 105 patients will be enrolled. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 105 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors |
| Actual Study Start Date : | December 1, 2017 |
| Estimated Primary Completion Date : | July 2020 |
| Estimated Study Completion Date : | December 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: CDX-1140
Dose-escalation phase: Eligible patients will receive treatments, based on cohort assigned, in 4 week cycles until progression or intolerance. Expansion phase: To further study the safety, tolerability, and efficacy of CDX-1140. Patients enrolled in the expansion phase of the study will receive CDX-1140 at the dose level(s) chosen during the escalation phase. |
Drug: CDX-1140
CDX-1140 will be administered every 4 weeks. |
- Safety and Tolerability of CDX1140-01 as assessed by CTCAE v4.0 [ Time Frame: Within 28 days after first dose ]The rates of drug-related adverse events, serious drug-related adverse events, dose-limiting toxicities, laboratory test abnormalities, and maximum tolerated dose will be determined.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed diagnosis of one of the following cancers: melanoma (including mucosal and/or ocular), bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast, colorectal, gastric, esophageal, renal cell, hepatic, ovarian, head and neck, and cholangiocarcinoma
-
Receipt of all standard therapies for the tumor type:
- Must have had all standard approved and unapproved therapies as deemed appropriate by the treating physician.
- Patients are not required to have all approved therapies in a drug class (e.g., patients with kidney cancer do not need all tyrosine kinase inhibitors, patients with melanoma do not need all approved checkpoint blockade inhibitors)
- Patients who refuse standard therapy are excluded from the study
- Measurable disease.
- Life expectancy ≥ 12 weeks.
- If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 6 months following last treatment.
- Willingness to undergo a tumor biopsy prior to treatment.
- Willingness to undergo a tumor biopsy while on study treatment.
Exclusion Criteria:
- History of severe hypersensitivity reactions to other monoclonal antibodies.
- Previous treatment with any anti-CD40 antibody.
- Received any antibody targeting T-cell check point or co-stimulation pathways within 4 weeks, received any other monoclonal antibody within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor) within 2 weeks prior to study treatment.
- Chemotherapy within 21 days (6 weeks for nitrosoureas) or at least 5 half-lives (whichever is longer) prior to study treatment.
- Received any kinase inhibitors within 2 weeks prior to study treatment.
- Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to study treatment.
- Major surgery within 4 weeks prior to study treatment.
- Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment.
- Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. For all other cancers, the patient must be disease-free for at least 3 years to be allowed to enroll.
- Active, untreated central nervous system metastases.
- Active autoimmune disease or documented history of autoimmune disease.
- Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C.
- Significant cardiovascular disease including Congestive Heart Failure or poorly controlled hypertension.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03329950
| Contact: Celldex Therapeutics | 844-723-9363 | info@celldex.com |
| United States, Arizona | |
| HonorHealth Research Insititute | Recruiting |
| Scottsdale, Arizona, United States, 85258 | |
| Contact: Michael Gordon, MD 480-323-1350 Michael.Gordon@honorhealth.com | |
| Contact: Monica Fulk, RN 480-323-1350 Monica.Fulk@honorhealth.com | |
| Principal Investigator: Michael Gordon, MD | |
| United States, New York | |
| Icahn School of Medicine at Mount Sinai | Recruiting |
| New York, New York, United States, 10029 | |
| Contact: Melissa Diamond 212-824-8449 Melissa.diamond@mssm.edu | |
| Principal Investigator: Nina Bhardwaj, MD | |
| Memorial Sloan Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Danny Khalil, MD 646-888-4384 khalild@mskcc.org | |
| Principal Investigator: Danny Khalil, MD | |
| United States, Oregon | |
| Providence Portland Medical Center | Recruiting |
| Portland, Oregon, United States, 97213 | |
| Contact: Brenda Fisher, RN 503-215-2613 Brenda.Fisher@providence.org | |
| Contact: Tara Foote, RN 503-215-7192 Tara.Foote@providence.org | |
| Principal Investigator: Rachel Sanborn, MD | |
| United States, Pennsylvania | |
| Abramson Cancer Center at the University of Pennsylvania | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Sagan Loburak 215-614-7677 Sagan.Loburak@uphs.upenn.edu | |
| Contact: Jennifer Louie 215-220-9668 Jennifer.Louie2@uphs.upenn.edu | |
| Principal Investigator: Mark O'Hara, MD | |
| Responsible Party: | Celldex Therapeutics |
| ClinicalTrials.gov Identifier: | NCT03329950 History of Changes |
| Other Study ID Numbers: |
CDX1140-01 |
| First Posted: | November 6, 2017 Key Record Dates |
| Last Update Posted: | June 28, 2018 |
| Last Verified: | April 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Keywords provided by Celldex Therapeutics:
|
CDX-1140 Solid Tumors Liver Cancer |
GI Cancer Kidney Cancer Celldex |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Adenocarcinoma Stomach Neoplasms Head and Neck Neoplasms Carcinoma, Renal Cell Esophageal Neoplasms Cholangiocarcinoma Carcinoma, Transitional Cell Liver Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Bronchogenic |
Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |